Last reviewed · How we verify
Budesonide MMX®
Budesonide MMX is a corticosteroid formulated with multi-matrix technology to deliver the active drug throughout the colon for localized anti-inflammatory effects in inflammatory bowel disease.
Budesonide MMX is a corticosteroid formulated with multi-matrix technology to deliver the active drug throughout the colon for localized anti-inflammatory effects in inflammatory bowel disease. Used for Ulcerative colitis (induction of remission), Crohn's disease (colonic involvement).
At a glance
| Generic name | Budesonide MMX® |
|---|---|
| Also known as | Cortiment®, Budesonide Multi-Matrix System |
| Sponsor | University of Calgary |
| Drug class | Corticosteroid (topical/colonic) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Immunology |
| Phase | Phase 3 |
Mechanism of action
Budesonide is a glucocorticoid receptor agonist that suppresses local immune and inflammatory responses in the colon. The MMX (multi-matrix) delivery system uses pH-dependent and time-dependent release mechanisms to ensure the drug is released gradually throughout the entire colon, maximizing therapeutic effect while minimizing systemic absorption and associated side effects.
Approved indications
- Ulcerative colitis (induction of remission)
- Crohn's disease (colonic involvement)
Common side effects
- Headache
- Abdominal pain
- Nausea
- Diarrhea
- Adrenal suppression (systemic corticosteroid effects)
Key clinical trials
- Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis (PHASE2)
- (CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis. (PHASE3)
- (CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis (PHASE3)
- (CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis (PHASE3)
- Effectiveness of Cortiment® in Patients With Ulcerative Colitis
- Cortiment® MMX Pharmacokinetic Study (PHASE1)
- Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budesonide MMX® CI brief — competitive landscape report
- Budesonide MMX® updates RSS · CI watch RSS
- University of Calgary portfolio CI